CD248 Rabbit anti-Human, Polyclonal, Invitrogen
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA520437
A suggested positive control is human colon tissue lysate. PA5-20437 can be used with blocking peptide PEP-0554. The PA5-20437 immunogen is located within amino acids 40-90 of TEM-1. Predicted molecular ~ 81kD. In Western blot applications, this antibody has been observed to detect a band at: 90 kD (post-modifications: 27 O-linked glycosylations). Predicted species reactivity based on immunogen sequence: Mouse (100%); Rat: (93%).Tumor endothelial marker (TEM) 1 was originally identified as a human embryonic fibroblast-specific antigen and was later determined to be endosialin, a single-pass transmembrane glycoprotein that has multiple extracellular domains, including three EGF-like domains, a sushi-like domain, and a C lectin-like domain. TEM proteins are significantly up-regulated during angiogenesis and neoangiogenesis that are crucial for the growth of solid tumors. While TEM1 is not required for angiogenesis during fetal development, postnatal growth or wound healing, it plays a role in tumor growth, invasion, and metastasis. Fibronectin and collagen types I and IV act as specific ligands of TEM1, leading to suggestions that these molecules may cause changes in the extracellular matrix, cell adhesion and migration during tumor invasion.
|A 14 amino acid peptide near the amino terminus of the human TEM1.|
|Antigen affinity chromatography|
|Human, Mouse, Rat|
|Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Western Blot|
|PBS with 0.02% sodium azide|
|CD164L1, MGC119478, MGC119479, TEM1, Tumor Endothelial Marker 1|
|Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok